Tuesday, April 22, 2014

How Congress Can Fight the Alzheimer's Epidemic

Not many people know it, but one of the best ways to curb future health-care spending is with a drug that slows the progression of Alzheimer's disease. Alzheimer's affects more than five million seniors today and last year cost Medicare and Medicaid almost $150 billion. By 2050, that number rises to 15 million cognitively impaired Americans whose care will cost more than $600 billion. According to a recent Alzheimer's Association study, women are twice as likely to get the disease than they are to get breast cancer. Last year, an estimated 450,000 Americans died with Alzheimer's. More …

Tuesday, April 22, 2014

Lilly's CYRAMZA™ (Ramucirumab) Becomes First FDA-Approved …

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA™ (ramucirumab) as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. With this approval, CYRAMZA becomes the first FDA-approved treatment for patients in this setting. More …

Tuesday, April 22, 2014

REM Sleep Disorder May Cause Alzheimer’s and Other Brain …

Dreaming may be the single most beautiful state of consciousness available to us on earth; our minds take flight while our bodies remain at rest. Unfortunately, those who suffer from sleep disorders may be cheated of one of life’s finest experiences while also wreaking havoc on their health. Now researchers at the University of Toronto have discovered that a particular sleep disorder that causes people to act out their dreams is a predictor of brain diseases such as Parkinson's and Alzheimer's. More …